Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence

Table 2 ≥ 50% Improvement in Incontinence Episodes or Other Symptoms: Treatment Success Definition by Intervention

Study	Study Design	Sample Size	Study Population	Comparator	Success Evaluated (months)	Success %
Botulinum toxin type A
Flynn, J Urol, 2004 [47]	Open Label	7	IOAB	None	3	100
Kuo, Urology, 2004* [48]	Open Label	12, 8	NOAB, IOAB	None	3, 3	66.6, 75
Kuo, Urology, 2005 [49]	Open Label	20	IOAB	None	3	85
Kalsi, Eur Urol, 2006* [50]	Open Label	63, 38	NOAB, IOAB	None	4, 4	86, 79
Kalsi, Ann Neurol, 2007 [51]	Open Label	43	NOAB	None	4	80
Mascarenhas, Neurourol. Urodynam, 2008 [38]	Open label	21	NOAB	None	2	52.4
Sacral neuromodulation
Schmidt, J Urol, 1999 [52]	RCT	34	IOAB	Current Management	6	75
Bosch, J Urol, 2000 [39]	Open Label	40	IOAB	None	47	60
Amundsen, Am J Obstet Gynecol, 2002 [53]	Open Label	12	IOAB	None	7	100
Bosch, J Urol, 2000 [39]	Open Label	6	NOAB	None	47	100
Hassouna, J Urol, 2000 [54]	RCT	25	IOAB	Current Management	6	56
Scheepens, Eur Urol, 2003 [55]	Open Label	34	IOAB	None	11	53
Van Voskuilen, BJU Int, 2007 [56]	Open Label	31	IOAB	None	15.5	90
Groenendijk, BJU Int, 2008 [57]	Open Label	67	IOAB	None	6	61
Wallace, Am J Obstet Gynecol, 2007 [58]	Open Label	33	NOAB	None	12.5	84.8
Augmentation cystoplasty
Blaivas, J Urol, 2005 [59]	Open Label	76	NOAB	None	106.8	97

* Denotes a study with both neurogenic OAB (NOAB) and idiopathic OAB (IOAB) populations.
Note: Studies may be listed in more than one category of treatment success if multiple definitions of treatment success were reported.

ISSN: 1471-2490